Details of the presentations are as follows:
|Format:||Presentation at the International Prader-Willi syndrome Meeting 2022 organized by INfoRMEd – PWS (the International Netwrok for Research, Managament and Education on adults with PWS) and the
|Title:||Long-Term Safety of Diazoxide Choline Extended-Release (DCCR) Tablets in Patients with Prader-Willi Syndrome|
|Format:||E-Poster -- Programme Code: EP360 / Submission Number 2044|
|Title:||Comparison of hyperphagia and problem behaviors in participants with Prader-Willi syndrome (PWS) receiving Diazoxide Choline Extended-Release (DCCR) with matched participants in PATH for PWS (PfPWS)|
|Format:||Poster -- Programme Code: P77 / Submission Number 789|
The copy of the posters will be available in the Investors section on the Company’s website at www.soleno.life after presentation at the meeting.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), is currently being evaluated in an ongoing Phase 3 clinical development program. For more information, please visit www.soleno.life.
Source: Soleno Therapeutics